In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE Marquette Medical Systems

Division of General Electric Co.

Latest From GE Marquette Medical Systems

TomoTherapy: Niche Player or Not?

Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?
Medical Device Strategy

Viasys Pulls Together

In under a year and a half, Viasys has transformed itself from a collection of 14 independent device companies to an integrated public company operating in four segments of the hospital market: respiratory, critical care, neurocare, and medical/surgical devices. As the successor to the companies that formerly made up the Thermo Biomedical division of Thermo Electron, it starts out with some unique challenges. It's already a public company with almost $400 million in revenues, so it has to be ever mindful of investors' expectations for growth. But it's virtually a start-up in terms of creating a corporate infrastructure and processes. Perhaps the greatest inherited weakness of Viasys is a lack of product-planning skills; Thermo Biomedical hadn't introduced a new product in seven years. Now Viasys must fill pipeline gaps with products that will appeal to its cost-conscious hospital constituency but still yield higher margins. Its middling size adds to the challenge; it's not big enough to afford a product failure, nor can it compete where financial might and product breadth are advantages. But Viasys believes it can handily apply the speed and maneuverability of a small firm to manufacture and market a large company-style product portfolio.
Medical Device Strategy

SpaceLabs Finds an Exit in Instrumentarium

Just as it did when it bought Datex-Ohmeda, the anesthesia equipment company, Instrumentarium has scooped up a US firm that built a US presence in an important technology area. This time the play is for SpaceLabs in critical care monitoring. For SpaceLabs, the acquisition ends a difficult time as it tried to remain independent in the face of a declining share price and heightened competition from some of capital equipment's largest players.
Medical Device Business Strategies

Making Anesthesiology More Science, Less Art

When it comes to monitoring patient consciousness levels during surgery, anesthesiology is as much art as science, traditionally relying on the anesthesiologist's judgment in the absence of instrumentation. The worst case result of this inexactitude, while rare, is everyone's worst nightmare, a condition called surgical awareness, where a patient is awake and can feel the pain but is paralyzed and unable to respond. The more common problem is the over-medication of patients, which results in accompanying side effects and longer recovery times. Aspect Medical has developed the first monitor to enable anesthesiologists to determine a patient's consciousness level to permit physicians to assess the amount of anesthesia necessary for sedation and track the risk of awareness. It's been a long haul for Aspect, which started in 1987 as a cardiology company and has survived a near bankruptcy and a pulled IPO along the way. But the result is the first major medical device IPO in nearly two years and a first mover advantage in a large market.
Medical Device Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register